GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.